© 2025 MJH Life Sciences™ , Patient Care Online – Primary Care News and Clinical Resources. All rights reserved.
Grace Halsey
Articles
Rocatinlimab, an OX40 Inhibitor, Achieves Positive Results in Atopic Dermatitis Treatment: ROCKET-Horizon Topline Findings
March 09, 2025
Approximately one-third of participants treated with rocatinlimab achieved EASI-75 at 24 weeks, more than 2 times the proportion in the placebo group, among other robust findings.
Dupilumab Demonstrates Superior Long-Term Persistence Over Upadacitinib and Tralokinumab in Atopic Dermatitis
March 09, 2025
Dupilumab was associated with the highest drug survival in monotherapy with nearly 90% of study participants remaining on treatment at both 12 and 24 months.
Atopic Dermatitis: It’s Not the Food, I Promise You
March 08, 2025
AAD 2025. Peter Lio, MD, from the Feinberg School of Medicine in Chicago, says, skip the elimination diet because food is rarely a cause of atopic dermatitis.
Rocatinlimab Shows Significant Efficacy in Moderate to Severe Atopic Dermatitis: Phase 3 IGNITE Trial Results
March 08, 2025
AAD 2025: The IGNITE study of the OX40 inhibitor included adults previously treated with a biologic or systemic JAK inhibitor, according to Amgen and Kyowa Kirin.
Lebrikizumab Improves Patient-Reported Outcomes in Atopic Dermatitis for Patients Previously Treated with Dupilumab
March 08, 2025
The proportion of participants with poor response to dupilumab who achieved a PNRS improvement of 3 points or greater was 72.9% at week 16 and 77.5% at week 24.
Ruxolitinib Cream Demonstrates Long-Term Disease Control in Atopic Dermatitis
March 07, 2025
By the end of the TRuE-AD1 and TRuE-AD 2 studies, 30.0% of participants met all 4 disease control criteria.
Roflumilast Foam 0.3% Significantly Reduces Pruritus and Improves Quality of Life in Scalp and Body Psoriasis
March 07, 2025
More than half (55.4%) of roflumilast-treated patients achieved a score of 0 or 1 vs 19.8% in the vehicle group on the Worst Itch-NRS numeric rating scale.
Roflumilast Cream 0.15% Well Tolerated in Atopic Dermatitis Patients with Prior Treatment Failures
March 07, 2025
Participants in the INTEGUMENT-1 and INTEGUMENT-2 phase 3 trials had failed treatment with topical corticosteroids and calcineurin inhibitors or crisaborole.
AAD 2025 preview: Dermatologist Mona Shahriari, MD, on Roflumilast and Other Nonsteroidal Topicals for Atopic Dermatitis
March 07, 2025
There are 3 classes of nonsteroidal topical therapies for atopic dermatitis that target the specific underlying pathophysiology of the skin disease. Shahriari provides a primer as physicians prepare for AAD 2025.
First Rivaroxaban Generics (2.5 mg) Get FDA Approval
March 05, 2025
The first low-dose rivaroxaban generic tablets to be FDA approved lead a field crowded with applications for formulations of all the higher doses.